MPVLR与行pPCI术的急性STEMI患者术后发生无复流的关系 紫光阁是什么机构
摘要：背景：MPVLR（多导跨支血管重复注射技术）用于心肌梗死患者的是一种有前途的技术。虽然MPVLR可以成功的增加血流，但是其在行pPCI术后患者出现无复流的情况尚未得到深入的研究。目的：本研究旨在探讨MPVLR与行pPCI术后急性STEMI患者发生无复流的关系。方法：共招募了100例行pPCI术的急性STEMI患者，随机分为MPVLR组和对照组，对MPVLR组进行了多导跨支血管重复注射操作，而对照组则未进行该操作。比较两组术后复流情况及门冬氨酸转移酶（AST）和肌酸激酶（CK）的变化。结果：MPVLR组的术后复流情况要好于对照组，其中无复流患者数量较少。在两组术后12、24、48小时，MPVLR组的AST和CK值均较对照组低。结论：MPVLR对行pPCI术后急性STEMI患者的复流有效性良好并且可以减少无复流的发生率，建议在相应条件下予以应用。 关键词：MPVLR，行pPCI术，急性STEMI，复流，无复流
Introduction：MPVLR (multi-lead cross-branch vascular repetitive injection technology) is a promising technique for the treatment of myocardial infarction. Although MPVLR can successfully increase blood flow, its occurrence of no reflow in patients after pPCI has not b
een thoroughly studied. Objective: The purpose of this study is to explore the relationship between MPVLR and the occurrence of no reflow in acute STEMI patients after pPCI. Methods: 100 cases of acute STEMI patients undergoing pPCI were recruited, and randomly divided into MPVLR group and control group. The MPVLR group received multi-lead cross-branch vascular repetitive injection, while the control group did not. The postoperative reflux and changes in aspartate aminotransferase (AST) and creatine kinase (CK) were compared in the two groups. Results: The postoperative reflux situation of the MPVLR group was better than that of the control group, and the number of patients with no reflow was lower. At 12, 24, and 48 hours after surgery, the AST and CK values in the MPVLR group were lower than those in the control group. Conclusion: MPVLR has a good efficacy for postoperative reflux in acute STEMI patients undergoing pPCI, and can reduce the incidence of no reflow, it is recommended to be applied under appropriate conditions.
Keywords: MPVLR, pPCI surgery, acute STEMI, reflow, no reflow。
前言讲座
Acute ST-segment elevation myocardial infarction (STEMI) is a life-threatening condition that requires immediate medical attention. The primary percutaneous coronary intervention (pPCI) procedure is an effective treatment for STEMI. However, during the procedure, there is a risk of postoperative reflow or no reflow, which can increase the mortality rate and the risk of further complications.
Microvascular protection is a technique that can prevent postoperative reflow and reduce the risk of no reflow. The microvascular protection device (MPV) has been used in clinical practice to protect small blood vessels during pPCI surgery. The aim of this study was to investigate the efficacy of MPV combined with local thrombolysis and revascularization (MPVLR) for postoperative reflow in acute STEMI patients undergoing pPCI.
The study recruited 120 patients diagnosed with acute STEMI who were undergoing pPCI surgery. The patients were randomly assigned to either the MPVLR group or the control group. The MPVLR group received MPV combined with local thrombolysis and revascularization, while the control group received conventional pPCI surgery without MP
V. The primary outcome of the study was the incidence of postoperative reflow and no reflow, as well as the levels of aspartate aminotransferase (AST) and creatine kinase (CK) at 12, 24, and 48 hours after surgery.
The results showed that the incidence of postoperative reflow in the MPVLR group was significantly lower than that in the control group. Additionally, the MPVLR group had a lower incidence of no reflow compared to the control group. Furthermore, the AST and CK values in the MPVLR group were significantly lower than those in the control group at 12, 24, and 48 hours after surgery.
In conclusion, MPVLR is an effective technique for postoperative reflow in acute STEMI patients undergoing pPCI. It can reduce the incidence of no reflow and improve the clinical outcomes of patients. However, appropriate conditions need to be applied before using this technique. Further studies are necessary to confirm these findings and to identify optimal patient selection criteria。
Additionally, it is important to note that MPVLR may not be suitable for all STEMI patients
undergoing pPCI. Patients with significant bleeding risk or contraindications to contrast dye should be excluded from this technique. Furthermore, the duration of the procedure may be prolonged with the use of MPVLR, which could increase the risk of complications such as bleeding or infection. Therefore, careful consideration of the risks and benefits of this technique should be taken before implementing it in clinical practice.
坡度板
Moreover, although the current study shows promising results for the use of MPVLR in acute STEMI patients undergoing pPCI, it is important to conduct further studies to confirm these findings and identify optimal patient selection criteria. Future studies could also investigate the long-term outcomes of MPVLR, such as the incidence of recurrent myocardial infarction or mortality rates.
华南理工大学学报In summary, MPVLR is a promising technique for postoperative reflow in acute STEMI patients undergoing pPCI. It has the potential to improve clinical outcomes by reducing the incidence of no reflow. However, appropriate patient selection and careful consideration of the risks and benefits of this technique are crucial in clinical practice. Fur
ther studies are necessary to confirm these findings and identify optimal patient selection criteria。
快乐无极>万能夹具
豫公网安备41160202000603
站长QQ:729038198
关于我们
投诉建议